Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a, Double Blind, Placebo-Controlled, Single-Center, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Volunteers

Next Previous
Trial Profile

A Phase 1a, Double Blind, Placebo-Controlled, Single-Center, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cudetaxestat (Primary)
  • Indications Cholangitis; Idiopathic pulmonary fibrosis; Inflammatory bowel diseases; Kidney disorders; Liver disorders; Non-alcoholic steatohepatitis; Scleroderma
  • Focus Adverse reactions
  • Sponsors Blade Therapeutics

Most Recent Events

  • 04 Sep 2022 According to a Blade Therapeutics media release, results from multiple phase I trials [NCT04146805, NCT04814472, NCT04939467 and NCT04814498] presented at European Respiratory Society (ERS) International Congress 2022
  • 04 Sep 2022 Results from multiple phase I trials [NCT04146805, NCT04814472, NCT04939467 and NCT04814498] published in the Blade Therapeutics Media Release
  • 22 Aug 2022 According to a Blade Therapeutics media release, data from four completed phase 1 studies[NCT04146805, NCT04814472, NCT04939467 and NCT04814498] will be presented at the at the European Respiratory Society (ERS) International Congress 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top